Export 28 results:
Author [ Title(Desc)] Type Year
Filters: Author is Barin, Burc  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
G. Omosa-Manyonyi, Park, H., Mutua, G., Farah, B., Bergin, P. J., Laufer, D., Lehrman, J., Chinyenze, K., Barin, B., Fast, P., Gilmour, J., and Anzala, O., “Acceptability and feasibility of repeated mucosal specimen collection in clinical trial participants in Kenya.”, PLoS One, vol. 9, no. 10, p. e110228, 2014.
B
C. Schmidt, Smith, C., Barin, B., Bakhtyari, A., Bart, P. - A., Bekker, L. - G., Chomba, E., Clumeck, N., Ho, D., Hoosen, A., Jaoko, W., Kaleebu, P., Karita, E., Keefer, M. C., van Lunzen, J., McMichael, A., Mehendale, S., Peters, B., Ramanathan, V. D., Robinson, A., Rockstroh, J., Vardas, E., Vets, E., Weber, J., Graham, B. S., Than, S., Excler, J. - L., Kochhar, S., Ho, M., Heald, A., and Fast, P. E., “Background morbidity in HIV vaccine trial participants from various geographic regions as assessed by unsolicited adverse events.”, Hum Vaccin Immunother, vol. 8, no. 5, pp. 630-8, 2012.
L. A. Frassetto, Tan-Tam, C. C., Barin, B., Browne, M., Wolfe, A. R., Stock, P. G., Roland, M., and Benet, L. Z., “Best single time point correlations with AUC for cyclosporine and tacrolimus in HIV-infected kidney and liver transplant recipients.”, Transplantation, vol. 97, no. 6, pp. 702-7, 2014.
G. Mutua, Farah, B., Langat, R., Indangasi, J., Ogola, S., Onsembe, B., Kopycinski, J. T., Hayes, P., Borthwick, N. J., Ashraf, A., Dally, L., Barin, B., Tillander, A., Gilmour, J., De Bont, J., Crook, A., Hannaman, D., Cox, J. H., Anzala, O., Fast, P. E., Reilly, M., Chinyenze, K., Jaoko, W., Hanke, T., and Group, T. Hiv- Core 0, “Broad HIV-1 inhibition in vitro by vaccine-elicited CD8(+) T cells in African adults.”, Mol Ther Methods Clin Dev, vol. 3, p. 16061, 2016.
C
L. Frassetto, Floren, L., Barin, B., Browne, M., Wolfe, A., Roland, M., Stock, P., Carlson, L., Christians, U., and Benet, L., “Changes in clearance, volume and bioavailability of immunosuppressants when given with HAART in HIV-1 infected liver and kidney transplant recipients.”, Biopharm Drug Dispos, vol. 34, no. 8, pp. 442-51, 2013.
R. Bahirwani, Barin, B., Olthoff, K., Stock, P., Murphy, B., and K Reddy, R., “Chronic kidney disease after liver transplantation in human immunodeficiency virus/hepatitis C virus-coinfected recipients versus human immunodeficiency virus-infected recipients without hepatitis C virus: results from the National Institutes of Health mu”, Liver Transpl, vol. 19, no. 6, pp. 619-26, 2013.
E
A. W Brooks, Zaman, K., Lewis, K. D. C., Ortiz, J. R., Goswami, D., Feser, J., Sharmeen, A. Tahia, Nahar, K., Rahman, M., Rahman, M. Ziaur, Barin, B., Yunus, M., Fry, A. M., Bresee, J., Azim, T., and Neuzil, K. M., “Efficacy of a Russian-backbone live attenuated influenza vaccine among young children in Bangladesh: a randomised, double-blind, placebo-controlled trial.”, Lancet Glob Health, vol. 4, no. 12, pp. e946-e954, 2016.
F
J. Nyombayire, Anzala, O., Gazzard, B., Karita, E., Bergin, P., Hayes, P., Kopycinski, J., Omosa-Manyonyi, G., Jackson, A., Bizimana, J., Farah, B., Sayeed, E., Parks, C. L., Inoue, M., Hironaka, T., Hara, H., Shu, T., Matano, T., Dally, L., Barin, B., Park, H., Gilmour, J., Lombardo, A., Excler, J. - L., Fast, P., Laufer, D. S., and Cox, J. H., “First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.”, J Infect Dis, vol. 215, no. 1, pp. 95-104, 2017.
H
M. V. Ragni, Humar, A., Stock, P. G., Blumberg, E. A., Eghtesad, B., Fung, J. J., Stosor, V., Nissen, N., Wong, M. T., Sherman, K. E., Stablein, D. M., and Barin, B., “Hemophilia Liver Transplantation Observational Study.”, Liver Transpl, vol. 23, no. 6, pp. 762-768, 2017.
I
A. Balagopal, Barin, B., Quinn, J., Rogers, R., Sulkowski, M. S., and Stock, P. G., “Immunologic Predictors of Liver Transplantation Outcomes in HIV-HCV Co-Infected Persons.”, PLoS One, vol. 10, no. 8, p. e0135882, 2015.
M
N. N. Nissen, Barin, B., and Stock, P. G., “Malignancy in the HIV-infected patients undergoing liver and kidney transplantation.”, Curr Opin Oncol, vol. 24, no. 5, pp. 517-21, 2012.
A. Subramanian, Sulkowski, M., Barin, B., Stablein, D., Curry, M., Nissen, N., Dove, L., Roland, M., Florman, S., Blumberg, E., Stosor, V., Jayaweera, D. T., Huprikar, S., Fung, J., Pruett, T., Stock, P., and Ragni, M., “MELD score is an important predictor of pretransplantation mortality in HIV-infected liver transplant candidates.”, Gastroenterology, vol. 138, no. 1, pp. 159-64, 2010.
O
P. G. Stock, Barin, B., Murphy, B., Hanto, D., Diego, J. M., Light, J., Davis, C., Blumberg, E., Simon, D., Subramanian, A., J Millis, M., G Lyon, M., Brayman, K., Slakey, D., Shapiro, R., Melancon, J., Jacobson, J. M., Stosor, V., Olson, J. L., Stablein, D. M., and Roland, M. E., “Outcomes of kidney transplantation in HIV-infected recipients.”, N Engl J Med, vol. 363, no. 21, pp. 2004-14, 2010.
N. A. Terrault, Roland, M. E., Schiano, T., Dove, L., Wong, M. T., Poordad, F., Ragni, M. V., Barin, B., Simon, D., Olthoff, K. M., Johnson, L., Stosor, V., Jayaweera, D., Fung, J., Sherman, K. E., Subramanian, A., J Millis, M., Slakey, D., Berg, C. L., Carlson, L., Ferrell, L., Stablein, D. M., Odim, J., Fox, L., and Stock, P. G., “Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection.”, Liver Transpl, vol. 18, no. 6, pp. 716-26, 2012.
P
S. Mehendale, van Lunzen, J., Clumeck, N., Rockstroh, J., Vets, E., Johnson, P. R., Anklesaria, P., Barin, B., Boaz, M., Kochhar, S., Lehrman, J., Schmidt, C., Peeters, M., Schwarze-Zander, C., Kabamba, K., Glaunsinger, T., Sahay, S., Thakar, M., Paranjape, R., Gilmour, J., Excler, J. - L., Fast, P., and Heald, A. E., “A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine.”, AIDS Res Hum Retroviruses, vol. 24, no. 6, pp. 873-80, 2008.
E. Vardas, Kaleebu, P., Bekker, L. - G., Hoosen, A., Chomba, E., Johnson, P. R., Anklesaria, P., Birungi, J., Barin, B., Boaz, M., Cox, J., Lehrman, J., Stevens, G., Gilmour, J., Tarragona, T., Hayes, P., Lowenbein, S., Kizito, E., Fast, P., Heald, A. E., and Schmidt, C., “A phase 2 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 vaccine based on adeno-associated virus.”, AIDS Res Hum Retroviruses, vol. 26, no. 8, pp. 933-42, 2010.
M. C. Keefer, Gilmour, J., Hayes, P., Gill, D., Kopycinski, J., Cheeseman, H., Cashin-Cox, M., Naarding, M., Clark, L., Fernandez, N., Bunce, C. A., Hay, C. M., Welsh, S., Komaroff, W., Hachaambwa, L., Tarragona-Fiol, T., Sayeed, E., Zachariah, D., Ackland, J., Loughran, K., Barin, B., Cormier, E., Cox, J. H., Fast, P., and Excler, J. - L., “A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults.”, PLoS One, vol. 7, no. 8, p. e41936, 2012.
G. Omosa-Manyonyi, Mpendo, J., Ruzagira, E., Kilembe, W., Chomba, E., Roman, F., Bourguignon, P., Koutsoukos, M., Collard, A., Voss, G., Laufer, D., Stevens, G., Hayes, P., Clark, L., Cormier, E., Dally, L., Barin, B., Ackland, J., Syvertsen, K., Zachariah, D., Anas, K., Sayeed, E., Lombardo, A., Gilmour, J., Cox, J., Fast, P., and Priddy, F., “A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults.”, PLoS One, vol. 10, no. 5, p. e0125954, 2015.
I. - U. H. Ansari, Allen, T., Berical, A., Stock, P. G., Barin, B., and Striker, R., “Phenotypic analysis of NS5A variant from liver transplant patient with increased cyclosporine susceptibility.”, Virology, vol. 436, no. 2, pp. 268-73, 2013.
S
F. M. Kibengo, Ruzagira, E., Katende, D., Bwanika, A. N., Bahemuka, U., Haberer, J. E., Bangsberg, D. R., Barin, B., Rooney, J. F., Mark, D., Chetty, P., Fast, P., Kamali, A., and Priddy, F. H., “Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial.”, PLoS One, vol. 8, no. 9, p. e74314, 2013.
G. Mutua, Sanders, E., Mugo, P., Anzala, O., Haberer, J. E., Bangsberg, D., Barin, B., Rooney, J. F., Mark, D., Chetty, P., Fast, P., and Priddy, F. H., “Safety and adherence to intermittent pre-exposure prophylaxis (PrEP) for HIV-1 in African men who have sex with men and female sex workers.”, PLoS One, vol. 7, no. 4, p. e33103, 2012.
W. Jaoko, Nakwagala, F. N., Anzala, O., Manyonyi, G. Omosa, Birungi, J., Nanvubya, A., Bashir, F., Bhatt, K., Ogutu, H., Wakasiaka, S., Matu, L., Waruingi, W., Odada, J., Oyaro, M., Indangasi, J., Ndinya-Achola, J., Konde, C., Mugisha, E., Fast, P., Schmidt, C., Gilmour, J., Tarragona, T., Smith, C., Barin, B., Dally, L., Johnson, B., Muluubya, A., Nielsen, L., Hayes, P., Boaz, M., Hughes, P., Hanke, T., McMichael, A., Bwayo, J., and Kaleebu, P., “Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa.”, Vaccine, vol. 26, no. 22, pp. 2788-95, 2008.
E. V. Millar, Bennett, J. W., Barin, B., Carey, P. M., Law, N. N., English, C. E., Schwartz, M. M., Cochrane, T., Ellis, M. W., Tribble, D. R., M Cooke, T., and Hennessey, J. P., “Safety, Immunogenicity, And Efficacy Of Ndv-3a Against Staphylococcus Aureus Colonization: A Phase 2 Vaccine Trial Among Us Army Infantry Trainees”, Vaccine, vol. 39, no. 23, pp. 3179-3188, 2021.
B. S. Peters, Jaoko, W., Vardas, E., Panayotakopoulos, G., Fast, P., Schmidt, C., Gilmour, J., Bogoshi, M., Omosa-Manyonyi, G., Dally, L., Klavinskis, L., Farah, B., Tarragona, T., Bart, P. - A., Robinson, A., Pieterse, C., Stevens, W., Thomas, R., Barin, B., McMichael, A. J., McIntyre, J. A., Pantaleo, G., Hanke, T., and Bwayo, J., “Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity.”, Vaccine, vol. 25, no. 11, pp. 2120-7, 2007.
J. Harbell, Fung, J., Nissen, N., Olthoff, K., Florman, S. S., Hanto, D. W., Light, J., Bartlett, S. T., Tzakis, A. G., Pearson, T. C., Barin, B., Roland, M. E., and Stock, P. G., “Surgical complications in 275 HIV-infected liver and/or kidney transplantation recipients.”, Surgery, vol. 152, no. 3, pp. 376-81, 2012.